
|Articles|October 1, 2002
Allergan, FDA communicate on Botox ads
Irvine, Calif. - Allergan Inc., contrary to popular belief, isn't fighting the U.S. Food and Drug Administration's allegations that statements in Botox Cosmetic advertisements are misleading, thus violating of the Food, Drug, and Cosmetic Act.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times - Dermatology News and Clinical Insights
1
STRATA Excimer Laser and JAK Inhibitors Delivers Superior Vitiligo Repigmentation
2
Vitiligo Disease Duration Linked to Depression Severity
3
APG777 May Ease Burden on Patients With AD
4
Evaluating Dose-Dependent Skin Changes from Long-Term Isotretinoin Therapy, Including CHE
5